Skip to main content
. Author manuscript; available in PMC: 2021 May 18.
Published in final edited form as: Nat Immunol. 2020 Nov 9;22(1):67–73. doi: 10.1038/s41590-020-00828-7

Extended Data Fig. 1. ROC curves with other characterized IgG1 glycans.

Extended Data Fig. 1

Receiver operating characteristic (ROC) curve for anti-RBD IgG1 IgG1 bisection (blue), galactosylation (green) and sialylation (yellow) from all hospitalized (n=43) and mild (n=18) COVID-19 patients showed these glycans were not predictors of COVID-19 severity. Area under the curve (AUC) for bisection 0.54[95% CI (0.38–0.69, p= 0.6357), galactosylation 0.61[0.42–0.81, p=0.1872 and sialylation 0.60[ 95% CI (0.40–0.79, p= 0.2245).